Astrazeneca, rigel pharma sign worldwide licensing pact to develop & commercialise fostamatinib disodium (pharmabiz)

2010-02-17 | Source

AstraZeneca and Rigel Pharmaceuticals announced an exclusive worldwide license agreement for the global development and commercialisation of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications.